Anticancer drugs: Cracking the combination

Bordon, Yvonne
July 2013
Nature Reviews Drug Discovery;Jul2013, Vol. 12 Issue 7, p505
Academic Journal
The article focuses on two studies published in the journals "Science" and "The Journal of Clinical Investigation" which examined new strategies for combining cancer immunotherapies. In one study, the CD47-binding domain of signal regulatory protein-α (SIRPα) was used as an antagonist for CD47. A mouse model of lymphoma was used to test the efficacy of SIRPα combined with tumour-specific antibodies. Another study found that CpG oligodeoxynucleotides have limited effect on tumors.


Related Articles

  • Boosting cancer immunotherapy. Visan, Ioana // Nature Immunology;Aug2013, Vol. 14 Issue 8, p776 

    No abstract available.

  • CD47 target: from theory to reality. Wu, John // Biomedical Research & Therapy;2014, Vol. 1 Issue 2, p35 

    Irving Weissman at the Stanford University School of Medicine in Palo Alto, California found that leukemia cells produced higher levels of CD47. This high expression help tumor cells to escape from the immune system. To date, the CD47 receptor becomes the interesting target in cancer treatment....

  • Comprehensive Behavioral Analysis of Cluster of Differentiation 47 Knockout Mice. Koshimizu, Hisatsugu; Takao, Keizo; Matozaki, Takashi; Ohnishi, Hiroshi; Miyakawa, Tsuyoshi // PLoS ONE;Feb2014, Vol. 9 Issue 2, p1 

    Cluster of differentiation 47 (CD47) is a member of the immunoglobulin superfamily which functions as a ligand for the extracellular region of signal regulatory protein α (SIRPα), a protein which is abundantly expressed in the brain. Previous studies, including ours, have demonstrated that...

  • Cryoimmunotherapy with local co-administration of ex vivo generated dendritic cells and CpG-ODN immune adjuvant, elicits a specific antitumor immunity. Alteber, Zoya; Azulay, Meir; Cafri, Gal; Vadai, Ezra; Tzehoval, Esther; Eisenbach, Lea // Cancer Immunology, Immunotherapy;Apr2014, Vol. 63 Issue 4, p369 

    Cryoablation is a low-invasive surgical procedure for management of malignant tumors. Tissue destruction is obtained by repeated deep freezing and thawing and results in coagulative necrosis and in apoptosis. This procedure induces the release of tumor-associated antigens and proinflammatory...

  • Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. Holbrook Kohrt, Aurélien; Sagiv-Barfi, Idit; Kohrt, Holbrook; Ajami, Bahareh; Axtell, Robert C.; Gang Zhou; Rajapaksa, Ranjani; Green, Michael R.; Torchia, James; Brody, Joshua; Luong, Richard; Rosenblum, Michael D.; Steinman, Lawrence; Levitsky, Hyam I.; Tse, Victor; Levy, Ronald // Journal of Clinical Investigation;Jun2013, Vol. 123 Issue 6, p2447 

    Activation of TLR9 by direct injection of unmethylated CpG nucleotides into a tumor can induce a therapeutic immune response; however, Tregs eventually inhibit the antitumor immune response and thereby limit the power of cancer immunotherapies. In tumor-bearing mice, we found that Tregs within...

  • CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma. James, Britnie; Anderson, Kristin; Brincks, Erik; Kucaba, Tamara; Norian, Lyse; Masopust, David; Griffith, Thomas // Cancer Immunology, Immunotherapy;Nov2014, Vol. 63 Issue 11, p1213 

    Tumor progression occurs through the modulation of a number of physiological parameters, including the development of immunosuppressive mechanisms to prevent immune detection and response. Among these immune evasion mechanisms, the mobilization of myeloid-derived suppressor cells (MDSC) is a...

  • Business as usual: the p35 isoform of human CD74 retains function in antigen presentation. Bergmann, Hannes // Immunology & Cell Biology;Oct2012, Vol. 90 Issue 9, p839 

    In this article, the author discusses the p35 isoform of human CD74. Ther author states human-specific CD74 isoform also known as p35 and contains a retention motif for the endoplasmatic reticulum (ER) and it is most enigmatic. The author further discusses the functions of CD74 in antigen...

  • Reply to 'On the Mechanism and Benefit of siRNA-mediated Targeting of CD47 in Cancer'. Wang, Yuhua; Xu, Zhenghong; Huang, Leaf // Molecular Therapy;Oct2013, Vol. 21 Issue 10, p1812 

    A reply by the authors to a letter to the editor about their study "On the Mechanism and Benefit of siRNA-mediated Targeting of CD47 in Cancer" is presented.

  • On the Mechanism and Benefit of siRNA-mediated Targeting of CD47 in Cancer. Zhao, Xiwen; Matlung, Hanke; Kuijpers, Taco W; van den Berg, Timo K // Molecular Therapy;Oct2013, Vol. 21 Issue 10, p1811 

    A letter to the editor is presented in response to the study "Intravenous Delivery of siRNA Targeting CD47 Effectively Inhibits Melanoma Tumor Growth and Lung Metastasis."


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics